Skip to main content
  • Original research
  • Open access
  • Published:

Phantom criteria for qualification of brain FDG and amyloid PET across different cameras



While fluorodeoxyglucose (FDG) and amyloid PET is valuable for patient management, research, and clinical trial of therapeutics on Alzheimer’s disease, the specific details of the PET scanning method including the PET camera model type influence the image quality, which may further affect the interpretation of images and quantitative capabilities. To make multicenter PET data reliable and to establish PET scanning as a universal diagnostic technique and a verified biomarker, we have proposed phantom test procedures and criteria for optimizing image quality across different PET cameras.


As the method, four physical parameters (resolution, gray-white contrast, uniformity, and image noise) were selected as essential to image quality for brain FDG and amyloid PET and were measured with a Hoffman 3D brain phantom and a uniform cylindrical phantom on a total of 12 currently used PET models. The phantom radioactivity and acquisition time were determined based on the standard scanning protocol for each PET drug (FDG, 11C-PiB, 18F-florbetapir, and 18F-flutemetamol). Reconstruction parameters were either determined based on the methods adopted in ADNI, J-ADNI, and other research and clinical trials or optimized based on measured phantom image parameters under various reconstruction conditions.

As the result, phantom test criteria were proposed as follows: (i) 8 mm FWHM or better resolution and (ii) gray/white %contrast ≥55 % with the Hoffman 3D brain phantom and (iii) SD of 51 small region of interests (ROIs) ≤0.0249 (equivalent to 5 % variation) for uniformity and (iv) image noise (SD/mean) ≤15 % for a large ROI with the uniform cylindrical phantom. These criteria provided image quality conforming to those multicenter clinical studies and were also achievable with most of the PET cameras that are currently used.


The proposed phantom test criteria facilitate standardization and qualification of brain FDG and amyloid PET images and deserve further evaluation by future multicenter clinical studies.


Brain PET imaging with fluorodeoxyglucose (FDG) and amyloid agents is promising for early and differential diagnosis of Alzheimer’s disease (AD) and is valuable for clinical research as well as for clinical trials of therapeutics [14].

However, PET image quality depends on the PET camera model and the specific reconstruction and acquisition details including injected activity, scan time, and reconstruction parameters, even if the radioactivity distribution is the same [5]. The image quality may affect image interpretation, quantitative capabilities, and even diagnostic capabilities, which makes it a challenge to acquire reliable data in a multicenter clinical study. To make PET a universal tool for research and therapeutic clinical trials as well as for patient management, the specific details of the scanning methods used should be “optimized” so that images of equivalent quality, both visually and quantitatively, can be obtained across different PET camera models.

In a well-controlled multicenter clinical research using PET on AD, such as Alzheimer’s Disease Neuroimaging Initiative (ADNI) [6], ADNI2 [7], and J-ADNI [8], and in industry-sponsored clinical trials [9, 10] on amyloid PET diagnostics or on therapeutics using brain FDG and amyloid PET, the PET QC manager has examined and qualified the PET cameras of each participating PET center based on phantom data. PET scanning details such as the reconstruction parameters are often determined during the qualification process so that images satisfying certain criteria can be obtained with each PET camera. However, no universally accepted phantom procedures and criteria have been published by academic societies. The details of the PET camera qualification procedures and criteria in industry-sponsored clinical trials are usually not open to the public.

In this work, we are proposing phantom procedures and criteria for qualification across different PET cameras to be used for brain FDG and amyloid PET imaging in multicenter studies. For that purpose, we first defined the elements of quality that are essential for brain FDG and amyloid PET images as physical parameters that are measurable in phantom experiments. Then, we examined the available details of PET scanning methods adopted in multicenter studies such as ADNI and J-ADNI and measured the physical parameters used with the phantoms to determine the “criteria,” based on which different PET cameras could be optimized. We also measured the physical parameters under various scanning conditions on a large number of PET camera models currently used in Japan to confirm that the criteria could be achieved by most of the currently used PET cameras under appropriate scanning conditions.

In terms of amyloid PET drugs, we dealt with 11C-PiB, 18F-florbetapir, and 18F-flutemetamol, because 11C-PiB has been used as a standard PET drug for research and the latter two 18F-labeled PET drugs are approved in many countries. 18F-florbetaben, which is also approved in many countries, was not dealt with in the present work because the PET camera used in the multicenter study for the efficacy of the PET drug was not available to us for the phantom experiments. However, the standard injection activity, scan time, % brain uptake, and other necessary information are provided in the “Discussion” section so that the readers can plan phantom experiments to evaluate a PET camera for 18F-florbetaben PET imaging.


Essential image quality for brain FDG PET

Detection and evaluation of localized hypometabolism is essential for the interpretation of FDG-PET images in research and clinical diagnosis regarding Alzheimer’s disease (AD) and other neurodegenerative disorders. AD is known to present a so-called AD pattern characterized by reduced FDG uptake in the temporoparietal cortex and in the posterior cingulate and precuneus, and other neurodegenerative disorders present other hypometabolic patterns [1]. Since FDG accumulates high in the cerebral cortex, PET images that have sufficient resolution provide structural information and help identification of lesion localization. The ring-shaped area along the contour of the brain on transaxial slices is called the cortical rim, which is actually a mixture of gray and white matter tissues interlacing each other. The apparent FDG uptake in the cortical rim reflects the proportion of gray matter tissue and is reduced if cortical atrophy occurs [11]. Therefore, poor resolution may make it difficult to distinguish pathological tissue hypometabolism from apparently decreased uptake due to atrophy.

In addition to the visual interpretation of FDG-PET images, the so-called statistical image analysis such as 3D-SSP is often used, in which the subject brain image is spatially normalized into a template and the relative regional uptake is compared voxel by voxel with the normal database to generate a z-map or t-map of significant hypometabolism [12, 13]. The z-map is either visually interpreted itself or further processed to generate a “score” representing the likelihood of the AD pattern [14, 15].

Therefore, FDG-PET images should have sufficiently high resolution and contrast together with sufficiently low noise to detect mild hypometabolism visually and quantitatively. Furthermore, image uniformity is also important because regional FDG uptake is evaluated as a relatively decreased activity in comparison with other areas both visually and quantitatively.

Essential image quality for brain amyloid PET

It is essential to detect and gauge abnormal cortical uptake in amyloid PET imaging as it reflects pathological deposition of amyloid beta plaque. A positive scan is characterized by such abnormal uptake and is found in most AD patients and in some cognitively normal elderly subjects, while a negative scan is characterized by the absence of such abnormal cortical uptake [16]. There are a number of PET drugs used for amyloid PET imaging, including 11C-PiB, 18F-florbetapir, 18F-florbetaben, and 18F-flutemetamol, but all of them accumulate non-specifically in the white matter [1720]. Therefore, it is necessary to detect mild cortical uptake adjacent to the non-specific uptake in the white matter, which requires sufficiently high resolution and contrast as well as low noise. In the case of cortical atrophy, this may often be a challenge.

Quantitative analysis of amyloid PET images is used as an adjunct to the visual interpretation as well as for the evaluation of disease progression and the monitoring of treatment. The ratio of cortex to cerebellum or pons as a reference region (SUVR) is the most frequently used indicator [19, 2123]. The quantitative measurement of the regional cortical uptake is influenced by a partial volume effect due to limited resolution, in which both spill-in from the white matter and spill-out into the CSF space occur [24]. Noise degrades the quantitative precision. Furthermore, quantitative capability is essential for the reference region. Therefore, uniformity within the field of view is also important in amyloid PET in addition to resolution, gray-white contrast, and noise.

Phantoms and physical parameters measured

Based on the above insights, we decided on the following four physical quality parameters for the phantom criteria and the phantoms to be used for measurement.

  1. (i)

    Resolution: Hoffman 3D brain phantom

  2. (ii)

    Gray-white contrast: Hoffman 3D brain phantom

  3. (iii)

    Uniformity: uniform cylindrical phantom

  4. (iv)

    Image noise: uniform cylindrical phantom

We chose the Hoffman 3D brain phantom (Data Spectrum Corporation, Durham North Carolina) because it is commercially available with a unique specification and because it simulates gray-matter and white-matter structures with 4:1 activity concentration, which is ideal for predicting the image quality of FDG-PET. A gray-white ratio of 4:1 is too high when it comes to detecting mild cortical uptake in amyloid PET, but it can still provide indicators of resolution and contrast and is considered instrumental for predicting the image quality of amyloid PET. The uniform cylindrical phantom has an inner diameter of 16 cm and an inner length of 30 cm and is also commercially available.

Table 1 presents the phantom radioactivity and the scan time (data acquisition time) adopted in the proposed phantom procedures to simulate a standard PET scan with each PET drug. They were derived from the standard injection activity, physical decay during the accumulation time, average brain uptake, and standard scan time for each PET drug, based on the following considerations.

Table 1 Phantom activity at start of scan and the interval to be extracted from list mode phantom data for each PET drug

Ideally, the phantom is to be filled with the amount of radioactivity that would exist in the brain at the start of the human PET scan, which is a function of injection activity, accumulation time (period between injection and start of emission scan, also called uptake time), and % brain uptake, and depends on the PET drug and protocol as well as on the pathological status of the subject. However, in view of efficiency and simplicity, we propose to determine a unique radioactivity value for each phantom regardless of the PET drug and the study protocol and to adjust the phantom scan time to match the activity-time product derived from the scanning protocol for each PET drug. As long as the injection activity is not too high for the count rate characteristics of the PET camera, as in most of the currently used PET cameras, the activity-time product determines the amount of available gamma ray counts. Practically, the phantom data are acquired in a long list mode so that the interval corresponding to each PET drug can be extracted and forwarded for image reconstruction. This allows phantom evaluation for two or more PET drugs in one experiment.

Table 2 presents the injection activity, accumulation time, and estimated brain activity at the start of scan for each PET drug that were used to derive the phantom experiment protocol proposed in this article. The injection activity is specified and standardized in most situations, and we adopted the values according to ADNI, ADNI2, J-ADNI, clinical trials of the PET drugs, and Japanese Society of Nuclear Medicine (JSNM) guidelines [710, 12, 2527]. The accumulation time should be standardized as much as possible because it affects the distribution of radioactivity, and we followed the standard methods adopted by previous studies. On the other hand, the scan time (duration of emission scan) has been variable and may even be determined specifically for each camera within the same project by phantom experiments through the qualification process, depending on the camera sensitivity. We adopted the standard scan time values written in the JSNM guidelines, which were based on previous studies and clinical trials, but they may be changed depending on the actual scan time. The % brain uptake depends on the pathophysiology, and we adopted the average values for each PET drug from the literature or through personal communication with investigators. Detailed explanations for each PET drug are given below.

Table 2 Scanning protocols and assumed brain activity at scan start that are used to derive the phantom methods of Table 1

For FDG, we followed the protocol of ADNI and J-ADNI, in which injection activity was 185 MBq, accumulation time was 30 min, and scan time was 30 min [28].

Formerly, the accumulation time of a typical brain FDG-PET study ranged from 45 to 60 min, when the regional uptake reflects glucose metabolism based on the tracer kinetics [29], which is necessary for quantitative measurement of glucose metabolism. However, if the purpose is identification of hypometabolic pattern and differential diagnosis, then a shorter accumulation time is equally effective because the regional blood flow, which the earlier scan reflects more, parallels the regional metabolism in neurodegenerative disorders [30]. The % brain uptake of FDG at 30 min post-injection was assumed to be 13 %ID based on the time-%ID curve for the brain [29] leading to estimated brain activity of 20 MBq at 30 min post-injection, with decay taken into account. This phantom activity is comparable to the 0.5–0.6 mCi that was used in the camera qualification process for ADNI [5].

For 11C-PiB, we also followed the protocol of ADNI and J-ADNI, in which injection activity was 555 MBq, accumulation time was 50 min, and scan time was 20 min. The % brain uptake was assumed to be 3 % (0.53 %IRD) based on the brain time-%IRD curve in a previous report [31] (%IRD denotes % injected radioactive dose, which is %ID with decay), leading to an estimated brain activity of 3 MBq.

For 18F-florbetapir and 18F-flutemetamol, standard injection activity was 370 and 185 MBq, accumulation time was 50 and 90 min, and standard scan time was 20 and 30 min, respectively. Although the package insert of 18F-florbetapir describes 10 min as the scan time, we have adopted a scan time of 20 min according to ADNI2 [32] and other research protocols and the JSNM guidelines [26]. Similar situations were found for the scan time of 18F-flutemetamol, of which the package insert indicated 20 min, but we adopted a scan time of 30 min according to the clinical trial protocols [33] and the JSNM guidelines [26].

The % brain uptake was assumed to be 4.5 %ID and 3.0 %ID based on the dosimetry study for 18F-florbetapir [34] and 18F-flutemetamol [35], leading to estimated brain activity of 12 and 3 MBq, respectively.

Amyloid-positive subjects present higher cortical uptake than amyloid-negative subjects (around 1.5 to 2 times the cortical SUV, depending on the PET drug [12, 17, 22, 23, 36]). However, a unique phantom protocol was determined for each PET drug, because the intensity and extent of increased uptake is variable among subjects and because it is important to detect mild cortical uptake rather than strong extensive uptake.

Phantom data acquisition

A Hoffman 3D brain phantom was filled with 20 MBq of 18F solution (FDG) at the start of scanning and scanned in a list mode or dynamic mode for 30 min together with a cylindrical phantom containing 80 MBq of 18F solution (FDG) placed on the bed 30 cm apart from the end of the phantom simulating the body activity. Data acquired during the “acquisition times” described in Table 1 were extracted from the list mode or dynamic mode data and reconstructed with specified or various parameters and post-filters. The scan of the uniform cylindrical phantom started when the activity decayed to 40 MBq and lasted for 30 min in a list or dynamic mode. Data acquired during the “acquisition times” described in Table 1 were extracted from the list mode or dynamic mode data and reconstructed with specified or various parameters and post-filters.

In the case of using a PET camera without list mode to acquire phantom data as the four PET drugs in Table 1, the Hoffman phantom data were acquired with a dynamic scan of four frames (135, 120, 455, and 1090 s). Averaged frames were provided for images to be evaluated. For example, the combination of the first (135 s) and second (120 s) frames is for flutemetamol (255 s).

To optimize the image reconstruction parameters, we vary the resolution and noise by changing iteration and subset combinations. In the case of particularly noisy images, we implemented Gaussian post-filters to control image noise, i.e., a gauss filter of 4 mm FWHM.

Phantom image analysis

Spatial resolution and gray/white contrast were computed from the Hoffman phantom images in the following manner. Spatial resolution was estimated from visual similarity between the Hoffman phantom image and the digital phantom obtained from the vendor treated with a 3D Gaussian filter of various FWHMs [37]. To derive the gray/white contrast, the JSNM region of interest (ROI) templates were defined on the digital Hoffman phantom that would provide a true gray-to-white ratio of 4 and were applied to the phantom image co-registered to the digital phantom (Fig. 1) [26, 38]. The %contrast was calculated as follows:

Fig. 1
figure 1

ROI template (red for gray matter, yellow for white matter) defined on the digital Hoffman phantom for evaluation of gray/white contrast

$$ \%\mathrm{contrast}=\frac{\left({\mathrm{GM}}_p/{\mathrm{WM}}_p-1\right)}{\left({\mathrm{GM}}_d/{\mathrm{WM}}_d-1\right)}\times 100 $$

where GM p and WM p were the ROI activity of gray matter and white matter measured on the phantom PET image, respectively, and GM d and WM d were the ROI activity of gray matter and white matter on the digital phantom, respectively.

The JSNM ROI templates were provided from gray/white sections in the Hoffman Digital Phantom Image and scraped along boundary voxels in order to avoid partial volume effect.

Uniformity and noise were evaluated in the uniform cylindrical phantom images in the following manner. For uniformity evaluation, 17 circular ROIs of 500 mm2 (uROI) were placed on the central slice and on two other slices ±40 mm apart from the central slice, making a total of 51 uROIs. The SDuROI mean was calculated as follows:

$$ {\mathrm{SD}}_{\mathrm{uROI}\ \mathrm{mean}}=\sqrt{\frac{1}{n}{\displaystyle \sum_{i=1}^n{\left(\frac{{\mathrm{uROI}}_{\mathrm{mean}}}{{\mathrm{uROI}}_{\mathrm{TOT}}}-1\right)}^2}} $$

where uROImean was the mean activity of each uROI, n = 51, and uROITOT was the average of the 51 uROImean.

For noise evaluation, a large circular ROI of 130 mm in diameter (nROI) was placed on the central slice. The coefficient of variation (CV) was calculated as follows:

$$ \mathrm{C}\mathrm{V}=\frac{{\mathrm{SD}}_{\mathrm{nROI}}}{{\mathrm{nROI}}_{\mathrm{mean}}}\times 100\ \left[\%\right] $$

where SDnROI was the standard deviation of the voxel values within the nROI and nROImean was the mean nROI activity.

Phantom evaluation under previous clinical protocols

Details of PET scanning methods of previous multicenter clinical study projects that had been carried out using FDG, PiB, 18F-florbetapir, or 18F-flutemetamol were collected from the literature, presentations at scientific meetings, or through personal communications from the investigators and PET QC managers of those projects. As a result, information about the PET camera model, injection activity, accumulation time, scan time, and reconstruction conditions were obtained for ADNI, J-ADNI, and clinical trials on efficacy of 18F-labeled amyloid PET drugs.

The phantom images were acquired based on the procedures described above using the PET cameras of the same model under the same scanning protocols as were used in those previous clinical studies, including injection activity, accumulation time, scan time, reconstruction conditions, and post-filters. The physical quality parameters (spatial resolution, gray-white contrast, uniformity, and image noise) were measured on the phantom images.

Phantom evaluation for currently used PET cameras

Phantom data were acquired on 19 PET cameras of 12 different models from 15 PET centers that participated in the J-ADNI2 project according to the procedures described above. The data for the four intervals corresponding to the four PET drugs described in Table 1 were extracted and reconstructed with various parameters and post-filters.

Table 4 shows the optimized reconstruction conditions that were selected and the physical parameters that were measured in this study. The detailed method for determining the optimized reconstruction parameters for an individual PET camera is reported by Akamatsu et al. [38].

Determination of phantom criteria

The phantom criteria were proposed based on these data so that it conforms to the image quality and quantitative capability provided by ADNI, J-ADNI, and clinical trials and so that most PET camera models could meet the criteria by selecting appropriate reconstruction parameters.


Table 3 summarizes the scanning conditions including the reconstruction parameters for each PET camera model used in PET scans with FDG, PiB, 18F-florbetapir, and 18F-flutemetamol in ADNI, ADNI2, J-ADNI, and clinical trials on 18F-florbetapir and 18F-flutemetamol. The phantom data were obtained according to the corresponding protocol, and the physical parameters measured on the phantom images were also presented. The spatial resolution was 9 mm FWHM or better in all cases and 7 mm FWHM or better in most of them. The %contrast ranged from 51.0 to 65.5 and was inversely associated with the FWHM values. The uniformity (SD) was below 0.0249, and the image noise ranged from 2.7 to 20.5.

Table 3 PET camera models and protocols used in clinical studies and physical parameters measured with phantoms

Figure 2 plots the %contrast measured with the Hoffman phantom against the image noise (CV) measured with the cylindrical phantom for the 12 PET camera models that were acquired with the protocol for each PET drug and reconstructed with the conditions that were considered appropriate in terms the trade-off between %contrast and image noise. For most PET cameras, optimized reconstruction conditions were found that provided %contrast 55 % or higher and image noise (CV) 15 % or lower. However, in three PET camera models, which were rather old types, no reconstruction conditions provided %contrast and image noise within the above range under the phantom protocol for one or more PET drugs. Figure 3 depicts such a case, in which changing the reconstruction parameters (subjects and iterations) and post-filter resulted in a trade-off between %contrast and image noise and did not reach an image that satisfies both criteria.

Fig. 2
figure 2

Scatter plots of %contrast and image noise (CV [%]) of phantom images reconstructed with optimized parameters for each camera and PET drug. Each point stands for each camera with adapted reconstruction parameter. Some camera needed to select parameters that were different from clinical settings. There was the trade-off between %contrast and image noise (CV [%])

Fig. 3
figure 3

Relationship between %contrast and image noise (CV) with the reconstruction parameter (96 iterative updates: iteration = 6 and subset = 16) and different post-filters (2, 4, and 6 mm FWHM Gaussian filter) for an old PET camera model measured with the phantoms under flutemetamol condition. Ninety-six iterative updates and other iterative updates (80 and 128, data not shown) did not satisfy the criteria (shaded region)

Based on these results, we decided to propose “55 % or higher” as the criteria for the %contrast and “15 % or lower” as the criteria for CV. We also propose 8 mm FWHM as the criteria for the spatial resolution, because the spatial resolution was 8 mm FWHM or better whenever %contrast was 55 % or higher. As for uniformity (SD), we adopted 0.0249 or lower.

In contrast with Table 3 of values obtained from national projects and clinical trials, Table 4 summarizes the optimized image results provided by optimized reconstruction parameters for 12 PET cameras. Most PET cameras met the criteria except for some old ones. The spatial resolution was 8 mm FWHM or better, and the uniformity (SD) was below 0.0249 in all models. The SD of 0.0249 corresponds to 95 % of the uROI mean values within 5 % of the mean assuming normal distribution.

Table 4 Phantom image performances acquired with reconstruction parameters optimized for each PET camera and for each PET drug


To make multicenter PET data reliable and to establish the PET scan as a universal tool for brain studies, we have proposed phantom test procedures and criteria to optimize the image quality across different PET cameras.

It should be emphasized that no theoretical absolutes exist as reference values for those physical parameters of the phantom test. If the reference values are set at a high level, then the PET images acquired in the multicenter study will be of higher quality, which may possibly lead to a result demonstrating higher diagnostic capability of the PET imaging for the study population. However, only a few PET camera models will meet the criteria and can be used for the study project, which may reduce the number of participating PET centers and, accordingly, limit the number of study cases. If a new PET drug is approved by the regulatory authorities based on the multicenter study data, and if the phantom criteria become a requirement for the PET camera to be used, the PET scan may not be readily available to the public. On the other hand, if the reference values are set at a low level, then all PET camera models will meet the criteria, and all PET centers will be able to participate in the multicenter study from the viewpoint of PET camera performance. However, the quality of the PET images may not be high enough to demonstrate the efficacy of a new PET drug.

It is desirable that the proposed criteria should conform to the image quality level at which multicenter clinical studies have been performed in order to obtain evidence of the efficacy of a PET drug or to build databases in the academic community, such as ADNI, ADNI2, J-ADNI, and clinical trials of 18F-florbetapir and 18F-flutemetamol. Therefore, phantom experiments were carried out to obtain the parameter values on the PET camera models that were used in the multicenter clinical studies under the scanning conditions specified for each camera. In such well-organized multicenter studies, the designated PET QC manager examines and qualifies the PET camera of each participating center with the phantoms by determining appropriate reconstruction conditions. Therefore, the scanning details adopted in such studies would provide credible information about the level of image quality that the PET images acquired with each PET drug should satisfy in general. One of the primary limitations of this method is that the gray-white ratios that are central to amyloid analysis are not well or directly tested with the Hoffman phantom. The Hoffman phantom may have applicable complexity in terms of anatomy, but not in terms of distributions, especially for amyloid PET scans. The distributions of the Hoffman phantom are not directly applicable to the method, in particular, the cerebellum and pons typically used as reference tissues.

It is also desirable that most of the currently used PET cameras should be able to meet the phantom test criteria under appropriate scanning conditions so that most PET centers can participate in a multicenter study that adopts the criteria. Therefore, the phantom experiments were also carried out on most PET camera models used in Japan to confirm that the criteria are achievable by selecting appropriate reconstruction conditions for most of them (Table 4). Naturally, the reference values in the criteria might change in the future according to the development and advent of new PET cameras with higher physical performance when older cameras are replaced by newer models.

To optimize the PET image quality between PET centers and between PET cameras in a multicenter study, the investigator is supposed to find such appropriate reconstruction parameters that will generate phantom images satisfying the criteria. The scan time (data acquisition time) may be adjusted depending on the sensitivity of the PET camera so that sufficient gamma ray counts are collected. For PET cameras with poor intrinsic performance, it may be difficult to find reconstruction parameters that will satisfy both resolution (%contrast) and noise, as depicted in Fig. 3, due to a trade-off between image resolution and noise. In this particular case, lengthening the scan time may suppress the noise without degrading the contrast. However, since Fig. 3 represents a case for 18F-flutemetamol, in which the standard clinical scan time is as long as 30 min, it may be practically difficult to make it any longer. If no reconstruction parameters or scan time are found for a certain PET camera that can generate phantom images satisfying the criteria, then the investigator may decide not to use the PET camera for a multicenter project. It is, of course, up to the investigator whether to conform strictly to the criteria or to allow some deviation.

As an 18F-labeled amyloid PET drug, 18F-florbetaben has also been developed and is commercially available in the USA, South Korea, and Europe [19]. The distribution of 18F-florbetaben in the brain is similar to 18F-florbetapir [39]; however, a difference between 18F-florbetapir and 18F-florbetaben, which is a nitrogen atom in the chemical structure, affects the pharmacokinetic properties and retention of the tracer in the target region. The imaging window for 18F-florbetaben providing the highest contrast between gray matter and white matter begins at 90 min post-injection. According to the sponsor company (Piramal Imaging), the standard injection activity, accumulation time, and scan time for 18F-florbetaben are 300 MBq, 90 min accumulation, and 20 min scan, respectively, and the average % brain uptake at 90 min post-injection was 3.5 %ID, based on the data of clinical trials in Japan, leading to the estimated brain activity of 6 MBq at scan start [26]. Therefore, the phantom data interval to be extracted for list mode data acquisition is 355 s for the Hoffman phantom (20 MBq at start) and 180 s for the cylindrical phantom (40 MBq at start) under standard scanning conditions.


Based on these considerations, we have proposed phantom criteria that will guarantee sufficient quality for multicenter brain PET studies and that can be met by most currently used cameras. The proposed criteria will help raise the quality of multicenter brain PET studies.


  1. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120–7.

    Article  CAS  PubMed  Google Scholar 

  2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ng S, Villemagne VL, Berlangieri S, Lee S-T, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med. 2007;48:547–52.

    Article  CAS  PubMed  Google Scholar 

  4. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–21.

    Article  CAS  PubMed  Google Scholar 

  5. Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. Neuroimage. 2009;46:154–9.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2005;1:55–66.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Jagust WJ, Landau SM, Koeppe RA, Reiman EM, Chen K, Mathis CA, et al. The Alzheimer’s disease neuroimaging initiative 2 PET Core: 2015. Alzheimers Dement. 2015;11:757–71.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Iwatsubo T. Japanese Alzheimer’s Disease Neuroimaging Initiative: present status and future. Alzheimers Dement. 2010;6:297–9.

    Article  PubMed  Google Scholar 

  9. Namiki C, Takita Y, Iwata A, Momose T, Senda M, Okubo Y, et al. Imaging characteristics and safety of florbetapir (18F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer’s disease. Ann Nucl Med. 2015;29:570–81.

    Article  PubMed  Google Scholar 

  10. Liu-Seifert H, Siemers E, Holdridge KC, Andersen SW, Lipkovich I, Carlson C, et al. Delayed-start analysis: mild Alzheimer’s disease patients in solanezumab trials, 3.5 years. Alzheimers Dement Transl Res Clin Interv. 2015;1:111–21.

    Article  Google Scholar 

  11. Yanase D, Matsunari I, Yajima K, Chen W, Fujikawa A, Nishimura S, et al. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging. 2005;32:794–805.

    Article  PubMed  Google Scholar 

  12. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6:221–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238–48.

    CAS  PubMed  Google Scholar 

  14. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302–16.

    Article  CAS  PubMed  Google Scholar 

  15. Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med. 2011;52:1218–26.

    Article  PubMed  Google Scholar 

  16. Gelosa G, Brooks DJ. The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging. 2012;39:1207–19.

    Article  CAS  PubMed  Google Scholar 

  17. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306–19.

    Article  CAS  PubMed  Google Scholar 

  18. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med. 2012;53:378–84.

    Article  CAS  PubMed  Google Scholar 

  19. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.

    Article  CAS  PubMed  Google Scholar 

  20. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.

    Article  PubMed  Google Scholar 

  21. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959–72.

    CAS  PubMed  Google Scholar 

  22. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J Nucl Med. 2010;51:913–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251–9.

    Article  CAS  PubMed  Google Scholar 

  24. Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2011;38:1104–19.

    Article  PubMed  Google Scholar 

  25. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer’s Disease Neuroimaging Initiative. Neuroimaging Clin N Am. 2005;15:869–77.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Standard PET imaging protocols and phantom test procedures and criteria: executive summary. Japanese Society of Nuclear Medicine website. Accessed 3 Oct 2016.

  27. Wizemann T, Pankevich DE, Altevogt BM. Future opportunities to leverage the Alzheimer’s disease neuroimaging initiative. Forum on Neuroscience and Nervous System Disorders; Institute of Medicine. Accessed 3 Oct 2016.

  28. Alzheimer’s Disease Neuroimaging Initiative PET technical procedures manual. ADNI website. Accessed 3 Oct 2016.

  29. Hays MT, Segall GM. A mathematical model for the distribution of fluorodeoxyglucose in humans. J Nucl Med. 1999;40:1358–66.

    CAS  PubMed  Google Scholar 

  30. Takahashi R, Ishii K, Senda M, Ito K, Ishii K, Kato T, et al. Equal sensitivity of early and late scans after injection of FDG for the detection of Alzheimer pattern: an analysis of 3D PET data from J-ADNI, a multi-center study. Ann Nucl Med. 2013;27:452–9.

    Article  CAS  PubMed  Google Scholar 

  31. O’Keefe GJ, Saunder TH, Ng S, Ackerman U, Tochon-Danguy HJ, Chan JG, et al. Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med. 2009;50:309–15.

    Article  PubMed  Google Scholar 

  32. ADNI 2 PET technical procedures manual AV-45 (florbetapir F 18) & FDG. ADNI website. Accessed 3 Oct 2016.

  33. Senda M, Miki T, Shimada H, Yamamoto Y, Kowa H, Kim JS, et al. Efficacy of [18F]flutemetamol in the Japanese population [abstract]. J Nucl Med. 2014;55 suppl 1:1869.

    Google Scholar 

  34. Lin K-J, Hsu W-C, Hsiao I-T, Wey S-P, Jin L-W, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent—a pilot study. Nucl Med Biol. 2010;37:497–508.

    Article  CAS  PubMed  Google Scholar 

  35. Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, Brooks DJ, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med. 2009;50:818–22.

    Article  CAS  PubMed  Google Scholar 

  36. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25:1528–47.

    Article  CAS  PubMed  Google Scholar 

  37. Hoffman EJ, Cutler PD, Guerrero TM, Digby WM, Mazziotta JC. Assessment of accuracy of PET utilizing a 3-D phantom to simulate the activity distribution of [18F]fluorodeoxyglucose uptake in the human brain. J Cereb Blood Flow Metab. 1991;11:A17–25.

    Article  CAS  PubMed  Google Scholar 

  38. Akamatsu G, Ikari Y, Nishio T, Nishida H, Ohnishi A, Aita K, et al. Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging. Ann Nucl Med. 2016;30:18–28.

    Article  CAS  PubMed  Google Scholar 

  39. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733–40.

    CAS  PubMed  Google Scholar 

Download references


We acknowledge all J-ADNI2 participating sites and J-ADNI2 PET QC core auditors for phantom data acquisition.

We also thank AVID/Eli Lilly (18F-florbetapir), GE Healthcare (18F-flutemetamol), and Piramal/SCETI (18F-Florbetaben) for providing the information from their respective clinical trials.

Phantom data were acquired from the following J-ADNI2 participating sites: Medical and Pharmacological Research Center (Ishikawa), Medical Imaging Clinic (Osaka), Aizawa Hospital (Nagano), Public Central Hospital of Matto Ishikawa (Ishikawa), The University of Tokyo (Tokyo), Tokyo Metropolitan Institute of Gerontology (Tokyo), Institute of Biomedical Research and Innovation (Hyogo), Kinki University Hospital (Osaka), Saitama Medical University International Medical Center (Saitama), Hamamatsu Medical Center (Shizuoka), National Institute of Radiological Sciences (Chiba), Kyushu University (Fukuoka), National Center for Geriatrics and Gerontology (Aichi), Iwate Medical University Cyclotron Research Center (Iwate), and Osaka University (Osaka).


This study was supported in part by JSPS KAKENHI Grant Number 15H04914.

This study was supported in part by “Research on the Development of Diagnostic Measures and Preventive Medicine for Early Stage Alzheimer’s Disease through a Combination of Brain Imaging, Clinical Research and Information Technology” sponsored by the New Energy and Industrial Technology Development Organization (NEDO) of Japan.

This study was supported in part by “Research on the Development of the National and International Collaboration to Support Dementia Clinical Research” sponsored by the Japan Agency for Medical Research and Development.

Authors’ contributions

YI drafted and developed the phantom test criteria and drafted the manuscript. GA participated in the data analysis and carefully revised the manuscript. TN carried out the phantom data acquisition and analysis. KIs and KIt provided the valuable information about the PET image quality in the J-ADNI project. TI designed and conducted the J-ADNI project as the Principal Investigator. MS designed the study and participated in the J-ADNI project as PET Quality Control manager and revised the manuscript critically. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Co-author of Tomoyuki Nishio joined Eli Lilly Japan in February 2016.

All of Nishio’s efforts in this study were conducted as a member of IBRI.

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Yasuhiko Ikari or Michio Senda.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ikari, Y., Akamatsu, G., Nishio, T. et al. Phantom criteria for qualification of brain FDG and amyloid PET across different cameras. EJNMMI Phys 3, 23 (2016).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: